Genomics Core

总结 在为服务不足的健康差距人口和代表性不足的人口提供服务的机构中， 学生（IUPS）之间的访问基因组学技术和所需的高成本 仪器、技术熟练程度和分析专业知识。基因组学核心（GC）解决了这一差距 通过以较低的费用提供专家和负担得起的高通量基因组学技术 所有合伙人调查员GC通过提供创新的方法来使整个伙伴关系受益， 探索早期的项目想法，并与伙伴关系调查人员及其受训人员合作，以促进使用 基因组学技术，以建立可持续的癌症生物学和癌症差异研究。完成 为了实现这些目标，GC（通过个性化癌症治疗中心，CPCT）提供 前沿基因组学相关技术以及对数据分析的生物信息学支持， 调查人员通过负担得起的报销模式。GC建议实现这些目标 通过追求旨在建设生物医学和癌症研究能力的四个具体目标， 在马萨诸塞大学波士顿分校的培训，弥合了尖端基因组学为基础的工具的可用性的差距;支持 希望追求早期项目想法的合作伙伴关系调查人员，特别是那些需要创新的项目。 和/或技术上具有挑战性的基因组学方法;弥合学生和高水平 基因组学为基础的技术，并提供生物信息学分析产生的数据的核心。在这 GC特别支持FP 2：靶向男性前列腺癌中的雄激素受体信号传导 与非洲制药公司- Steven Balk（DF/HCC - BIDMC）和Changmeng Cai（马萨诸塞大学波士顿分校）和PP 2：高 BRCA 2缺陷型非裔美国人前列腺肿瘤中CHD 1丢失的频率导致治疗耐药性- Zoltan Szallasi（DF/HCC-BCH）和Shailja Pathania（马萨诸塞大学波士顿分校）。

SUMMARY A critical gap often exists at institutions serving underserved health disparity populations and underrepresented students (ISUPS) between access to Genomics technologies and the high costs associated with the required instrumentation, technical proficiency, and analytical expertise. The Genomics Core (GC) addresses this gap by providing expert and affordable access to high-throughput genomics technologies on a reduced fee basis for all Partnership investigators. The GC benefits the entire Partnership by providing innovative approaches to explore early project ideas, and by working with Partnership investigators and their trainees to facilitate the use of genomics technologies to build sustainable cancer biology and cancer disparities research. To accomplish these goals, the GC (through the auspices of the Center for Personalized Cancer Therapy, CPCT) provides front-line genomics-related technologies, as well as bioinformatics support for data analysis, to Partnership investigators through an affordable reimbursement model. The GC proposes to accomplish these goals through the pursuit of four specific aims designed to build capacity for biomedical and cancer research and training at UMass Boston by bridging a gap in the availability of cutting-edge genomics-based tools; support Partnership investigators who wish to pursue early project ideas, especially those that require innovative and/or technically challenging genomics approaches; bridge a training gap between students and high-level genomics-based technologies, and provide bioinformatics analysis of data generated in the core. In this application, the GC specifically supports FP2: Targeting androgen receptor signaling in prostate cancer in men with African Ancestry – Steven Balk (DF/HCC - BIDMC) and Changmeng Cai (UMass Boston) and PP2: High frequency of CHD1 loss in BRCA2-deficient African American prostate tumors drives treatment resistance – Zoltan Szallasi (DF/HCC - BCH) and Shailja Pathania (UMass Boston).